AI and Data Analytics Enhance Screening Accuracy
the market’s value to rise from USD 3.40 billion in 2024 to USD 5.60 billion by 2032, at a CAGR of 10.20%. POC adoption not only enhances accessibility but also strengthens early detection of infectious markers, helping to maintain transfusion safety even in challenging conditions.
AI and Data Analytics Enhance Screening AccuracyArtificial intelligence and machine learning are transforming the Blood Screening Market by improving test interpretation and operational efficiency. AI-driven algorithms can analyze complex molecular assay data, flagging anomalies and reducing the chances of false positives or negatives. Integration with laboratory information systems (LIS) also streamlines result validation and reporting. MRFR estimates the market will increase from USD 3.40 billion in 2024 to USD 5.60 billion by 2032. These digital innovations are critical for high-volume testing centers, where manual review of results is time-consuming. As AI systems continue to learn from global datasets, they will play a pivotal role in predicting emerging threats and adapting screening protocols faster than traditional methods.